Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

654
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
654
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

243
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
243
Sedatives and Hypnotics Drugs: Barbiturates01:20

Sedatives and Hypnotics Drugs: Barbiturates

480
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A...
480
Sedatives and Hypnotics Drugs: Benzodiazepines01:19

Sedatives and Hypnotics Drugs: Benzodiazepines

388
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
388
Stages of General Anesthesia01:22

Stages of General Anesthesia

714
Various sedation levels offer significant advantages in facilitating procedural interventions for patients undergoing medical or invasive surgical procedures. These levels span from anxiolysis to general anesthesia, providing a spectrum of sedative effects to cater to specific patient needs. Anxiolysis reduces anxiety and is achieved through minimal sedation, enabling patients to remain awake and responsive while feeling more at ease during the procedure. This level can benefit minor...
714
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

472
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
472

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Double effect sedation: reply to commentaries.

Journal of medical ethics·2025
Same author

Intending to avoid the treatment burdens only: the doctrine of double effect and withholding or withdrawing life-sustaining treatment.

Theoretical medicine and bioethics·2025
Same author

Continuous deep sedation and the doctrine of double effect: Do physicians not intend to make the patient unconscious until death if they gradually increase the sedatives?

Bioethics·2020
Same author

An International Legal Review of the Relationship between Brain Death and Organ Transplantation.

The Journal of clinical ethics·2018
Same author

Integration of palliative and supportive cancer care in Asia.

The Lancet. Oncology·2012

Related Experiment Video

Updated: Sep 13, 2025

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
07:54

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

20.0K

Double-effect sedation: do physicians not intend a decrease in consciousness when it is caused by drugs that can also

Hitoshi Arima1

  • 1Graduate School of Urban Social and Cultural Studies, Yokohama City University, Yokohama, Kanagawa, Japan harima@buffalo.edu arima@yokohama-cu.ac.jp.

Journal of Medical Ethics
|July 25, 2025
PubMed
Summary

Palliative sedation ethics are complex. Double-effect sedation (DES) uses drugs for symptom relief and sedation, but physicians often intend to reduce consciousness, challenging ethical justifications.

Keywords:
Pain ManagementPalliative CareTerminal Care

More Related Videos

Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers
14:52

Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers

Published on: January 13, 2018

11.1K
Assessing Changes in Volatile General Anesthetic Sensitivity of Mice after Local or Systemic Pharmacological Intervention
08:49

Assessing Changes in Volatile General Anesthetic Sensitivity of Mice after Local or Systemic Pharmacological Intervention

Published on: October 16, 2013

13.8K

Related Experiment Videos

Last Updated: Sep 13, 2025

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
07:54

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

20.0K
Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers
14:52

Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers

Published on: January 13, 2018

11.1K
Assessing Changes in Volatile General Anesthetic Sensitivity of Mice after Local or Systemic Pharmacological Intervention
08:49

Assessing Changes in Volatile General Anesthetic Sensitivity of Mice after Local or Systemic Pharmacological Intervention

Published on: October 16, 2013

13.8K

Area of Science:

  • Medical Ethics
  • Palliative Care
  • Pharmacology

Background:

  • Palliative sedation is ethically debated, particularly when sedating drugs also alleviate symptoms.
  • Drugs like midazolam and morphine can reduce symptoms (seizures, pain, dyspnea) while also lowering consciousness.
  • This dual action is termed double-effect sedation (DES).

Purpose of the Study:

  • To examine the ethical claims surrounding double-effect sedation (DES).
  • To investigate whether the reduction in consciousness in DES is always an unintended side effect.
  • To determine if the doctrine of double effect (DDE) can ethically justify DES.

Main Methods:

  • Analysis of ethical arguments concerning palliative sedation and the doctrine of double effect.
  • Examination of clinical scenarios where sedating drugs are used for symptom management.
  • Philosophical inquiry into the intentionality of physicians' actions in DES.

Main Results:

  • The claim that reduced consciousness in DES is merely a side effect is often false.
  • Physicians frequently intend to reduce consciousness when administering DES.
  • Foreseen or prolonged reduction in consciousness does not automatically make it a side effect.

Conclusions:

  • The doctrine of double effect (DDE) may not justify DES when consciousness reduction is intended.
  • DES, especially when consciousness is an intended effect, requires rigorous moral evaluation.
  • Such cases should be assessed similarly to sedating drugs without symptom-alleviating properties.